anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur in uncomplicated influenza as well. 

There have been postmarketing reports of delirium and abnormal behavior leading to injury in patients with influenza who were receiving neuraminidase inhibitors, including RAPIVAB. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made, but they appear to be uncommon. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of RAPIVAB to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to preparing agent for treatment of allergic rhinitis and allergic conjunctivitis. Agent comprises a base and cytokines taken among the group: recombinant alpha-, beta-, gamma-interferon taken in the amount 1 000-100 000 IU per 1 g of agent; antihistaminic preparations taken among the group: diazolinum, mebhydrolin, antazoline, ebastin, loratadine, levocabastine, azelastine, astemizol, terfenadine, diphenhydramine, chloropyramine, cetirizine, promethazine taken in the amount 0.0001-0.1 g per 1 g of agent; corticosteroid preparations taken among the group: hydrocortisone, fludrocortisone, flumetasone, betamesone, mometasone, ftorcortolone, triamcinolone, prednisone, prednisolon, dexamethasone taken in the amount 0.002-0.01 g per 1 g of agent. Agent comprises additionally anti- inflammatory preparations taken among the group: sodium diclofenac, indometacin, ibuprofen, naproxen; antibacterial agent taken among the group: dioxydin, zinc sulfate, myramistin; antibiotics with broad spectrum of effect, methylbenzethonium chloride, cetylpyridonium chloride, alkyltrimethylammonium bromide, chlorhexidine gluconate, iodopovidonum, imidiazinylurea, diazolidine urea. Agent comprises also additionally regulators and stabilizers of cellular functions taken among the group: theophylline, sodium cromoglicate, sodium nedocrimal, vitamins and it comprises also vasoconstrictive preparations taken among the group: xylometazoline, naphazoline, oxymetazoline, tetryzoline, phenylephrine. As a base the agent comprises one or some components taken among the group of additions including: vaseline, glycerol, polyethylene oxide, propylene glycol, vegetable oil, essential oil, silicone oil. Invention provides the development of highly effective agent for treatment of allergic rhinitis and allergic conjunctivitis. EFFECT: improved preparing method, enhanced effectiveness and valuable medicinal properties of agent. 6 cl
Osteoarthritis (OA) is commonest chronic arthritis affecting patients usually aged above 45 years. OA decreased health-related quality of life and increased economic costs. Radiofrequency (RF), was used for the treatment of chronic pain unresponsive to conservative therapies. RF has been used for several painful conditions. There have been a few attempts to use RF current for the treatment of painful conditions of joints of the extremities. It was also used for the treatment of painful conditions of the hip joint.
Primary Sjögren's syndrome is a complex autoimmune disease involving the exocrine salivary and lachrymal glands, with a progressive functional impairment caused by lymphocytic infiltration in the glandular tissue. The diagnosis is currently performed according to the criteria established in 2016 by the American College of Rheumatologists/European League Against Rheumatism (ACR/EULAR) and relies on 5 items, namely i) histologic Focus Score (FS) ≥1, ii) positivity to Anti-SSA (Ro) antibodies, iii) Ocular staining score ≥ 5 (or van Bijsterfeld score ≥ 4) on at least one eye, iv) Schirmer test ≤ 5 mm/5min on at least one eye and v) Unstimulated Salivary Flow Rate (USFR) ≤ 0.1 ml/min. Focus Score and positivity to antibodies are items with a weight of 3 points each, while the other items are assigned score 1. Diagnosis is performed with a total score ≥ 4 when summing the weights. While the improvement in the sensitivity of ACR/EULAR classification criteria by 5-10% has been previously reported for ultrasonography of major salivary glands, at present no evidence is available for minor salivary glands. Minor salivary glands ultrasonography with the use of ultra-high frequencies up to 70 MHz has been recently introduced in the diagnostic work-up of Sjögren's syndrome, and involves the assessment of glandular ultrasonographic structural alterations through the application of the Outcome Measures in Rheumatology (OMERACT) scoring system, which is routinely used for major salivary glands. The present study therefore aims to assess the correlation between minor salivary glands ultrasonography and ACR/EULAR items, in order to evaluate whether this technique may integrate the current evaluation of Sjögren's syndrome patients.
This study aimed to evaluate the early introduction of ultra-processed foods (UPF) and identify its association with overweight and anaemia in Brazilian children living in a situation of social vulnerability. A population-based cross-sectional study was conducted in a Brazilian capital. Children aged 12-59 months were included. The presence of overweight and anaemia was evaluated, as well as the introduction of twelve different UPF in children's first year of life. Association analysis was performed using Poisson regression, with robust estimates of variances. A total of 561 children were studied; 85·5 % had consumed at least one UPF evaluated in the first year of life; 19·1 % were overweight and 52·0 % were anaemic. Adjusted multivariate analyses identified that the early introduction of soft drinks (Prevalence Ratio (PR) = 1·18, 95 % CI (1·02, 1·38)), packaged snacks (PR = 1·17, 95 % CI (1·05, 1·30)) and powdered soft drinks (PR = 1·36, 95 % CI (1·16, 1·60)) increased the likelihood of children being overweight, and the early introduction of chocolate drink (PR = 1·25, 95 % CI (1·02, 1·53)) increased the likelihood of them being anaemic, when comparing children who consumed these UPF before reaching 1 year of age with those who consumed these foods at 12 months of age or older. From the results found, one can see the existing relationship between the early introduction of UPF with overweight and anaemia, being necessary to intensify public health policies to combat malnutrition, focusing on the promotion of proper and healthy eating, especially during the phase of food introduction, focusing on the population living in socially vulnerable situations.
Superantigens, including staphylococcal enterotoxins, are useful agents in the killing of tumor cells, the enhancement of antitumor immunity and in the treatment of cancer in a tumor-bearing host. In particular, the immune system of a subject with cancer is contacted with tumor cells that have been transfected with nucleic acid encoding a superantigen or biologically active polypeptide of a superantigen. Alternatively, transfected accessory cells, immunocytes or fibroblasts are used. When the superantigen is expressed in the host, T cell proliferation is induced leading to increased antitumor immunity and tumor cell killing. The nucleic acid encoding a superantigen may be administered to the tumor in vivo to transfect tumor cells wherein superantigen expression induces a similar tumoricidal immune response. Also disclosed are methods for treating a tumor wherein the transfected cells described above are incubated ex vivo with an immunocyte population, particularly T lymphocytes, to tumoricidally activate the population, followed by administering the activated population to the tumor-bearing host. Superantigens useful in these methods also include Streptococcal pyrogenic exotoxin, toxic shock syndrome toxins, mycoplasma antigens, mycobacteria antigens, minor lymphocyte stimulating antigens, heat shock proteins, stress peptides and derivatives thereof.
A nanostructured biocompatible wafer for placement in the conjunctival cul-de-sac. The wafer contains a tissue-reactive mucoadhesive polymer and a mesh formed of a plurality of hydrophobic polymer fibers. Also provided is a method for treating glaucoma, an ocular surface disorder, or an ocular surface infection using the nanostructured biocompatible wafer. Additionally, an injectable sustained-release formulation for treating an ocular disorder is disclosed. The formulation includes a drug contained within a plurality of microparticles formed of a biodegradable polymer and are coated with a tissue-reactive compound. Further provided is a method for treating an ocular disorder by injecting the microparticulate sustained release formulation.
1425429 Benzoxazolinone derivatives INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 24 June 1974 [26 June 1973] 27952/74 Heading C2C Novel compounds have the Formula I: m which R 1  represents a hydrogen atom, an unsubstituted or substituted alkyl group containing 1 to 6 carbon atoms, an unsubstituted or substituted phenyl or benzyl group or a thienyl group, R 2  represents a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, and X represents a hydrogen atom and Y represents a hydroxy group or X and Y together represent an oxo group. The compounds of Formula I in which R 1  is other than a hydrogen atom are obtained by reacting in the presence of polyphosphoric acid a compound of Formula II: with an acid of formula R 1 COOH or a functional derivative thereof (e.g. anhydride or chloride) to form a compound of Formula I wherein X and Y together represent an oxo-group, the corresponding alcohol of Formula I being obtained therefrom by reduction (e.g. NaBH 4 ). The compounds of Formula I wherein R 1  represents a hydrogen atom are prepared by reacting in the presence of polyphosphoric acid a compound of Formula II with hexamethylenetetramine to form the 6-formyl benzoxazolinone derivative of Formula I, the corresponding hydroxymethyl derivative being again obtained by reduction. The examples prepare compounds of Formula I in which R 1  is -CH 3 , -C 2 H 5 , -CH 2 Cl, -C 6 H 5 , -CH 2 C 6 H 5 , thienyl and hydrogen and R 2  is hydrogen or -CH 3 .
The invention discloses a traditional Chinese medicine ointment curing hemorrhoids, and belongs to the technical field of traditional Chinese medicine. According to the technical scheme, the traditional Chinese medicine ointment comprises, by weight, 10-15g of calamine, 6-10g of lead tetraoxide, 6-9g of sangusis draconis, 6-9g of cinnabar, 10-15g of talcum powder, 6-9g of Acacia catechu, 6-9g of dragon bones, 6-9g of hydrargyrum oxydatum crudum, 3-6g of olibanum, 3-6g of myrrh, 2 parts of calomel, 1-3 pieces of borneol, 3-6g of fructus cnidii and 6-9g of concha arcae. The traditional Chinese medicine is mixed, porphyrized and sieved, and then the traditional Chinese medicine and sulphur ointment are made into the ointment according to the ratio which is 25-50%. According to the traditional Chinese medicine ointment, the components can be got easily, and cost is low. The ointment takes effect rapidly, has a short treatment period, is convenient to use, is non-poisonous, has no side effect, has an obvious curative effect on internal hemorrhoids, external hemorrhoids and combined hemorrhoids, and allows the cure rate to reach more than 98%. Meanwhile, the traditional Chinese medicine ointment also has a good curative effect on anal fissure, abscess and anal fistula.
INTRODUCTION: Benign tracheobronchial stenosis is a abnormal tracheal lumen narrowing that may incur progressive dyspnea and life-threatening hypoxemia. There is no consensus on which patients should be treated with endoscopic or surgical method. This study investigates the outcomes of bronchoscopic dilatation in the treatment of benign tracheal stenosis using a device equipped with a blade to cut the stenotic lesions with dense fibrosis.
MATERIALS AND METHODS: The procedure was carried out in an operating room under general anesthesia. All patients were intubated with a Rigid Bronchoscope (RB) placed just above the stenosis. Through Rigid Bronchoscopy combined modalities were used as needed: radial incisions of the mucosal stenosis with blade at the levels of 4, 8 and 12 o'clock, with back and forth movements, then the stenotic area was dilated more easily with a rigid bronchoscope. Dilatation was performed by passing the RB of increasing diameter through stenotic areas and then Balloon dilatation of increasing diameter. There were no complications during the procedure.
RESULT: We conducted an observational, retrospective, single-centre study in the Thoracic Surgery Unit of the University of 'Luigi Vanvitelli' of Naples from November 2011 to September 2021. We included all consecutive patients with benign tracheal stenosis inoperable. During the study period, 113 patients were referred to our department with benign tracheal stenosis inoperable. 61 patients were treated with the blade. During the follow-up, a recurrence of the stenosis was observed in 8 patients in the first month and in 4 patients in the third month. Instead in the patients treated with the use of laser (52 patients), during the follow-up a recurrence was observed in 16 patients in the first month and in 6 patients in the third month; no patient relapsed after 6 months and after 1 year. Long term successful bronchoscopic management with blade was attained by 99% in simple and 93% in mixed stenosis and in complex type stenosis.
CONCLUSION: Our study underlines the importance of the use of the blade in bronchoscopic treatment as a valid conservative approach in the management of patients with inoperable benign tracheal stenosis as an alternative to the use of the laser, reducing the abnormal inflammatory reaction in order to limit recurrences.
Necrotic enteritis (NE) is a disease of worldwide distribution, which affects young broilers and causes economic losses on a scale of 6 billion dollars per year. For decades, NE was controlled in poultry flocks by dietary administration of low doses of antimicrobial growth promoters (AGPs). However, an increase in NE incidence was noted after the AGP ban. This study aimed to compare the effect of an antibiotic (Enramycin) diet to a combination of sodium butyrate, hydrolyzed yeast, and zinc proteinate (ViligenTM) on broiler diets regarding performance, blood parameters, intestinal permeability, morphology and lesions, and carcass yield of broilers challenged with Eimeria spp. and Clostridium perfringens to simulate subclinical necrotic enteritis. A total of 1,150 one-day-old male broiler chickens with an initial average weight of 43.9 ± 0.65 g were allocated to 50 experimental pens. Animals were divided into 5 groups: Negative control (NC) without additives; Positive control (PC) with 0.12 g/ton of Enramycin (8%); V500, V1000, and V1500 with the addition of 500, 1.000, and 1.500 g/ton of Viligen, respectively. All animals were challenged by Eimeria spp. at 7 d of age and by C. perfringens at 17, 18, and 19 d for induction of subclinical NE. The broilers fed with all concentrations of Viligen showed similar performance, blood parameters, intestinal permeability, and carcass yield compared to PC broilers. However, NC broilers showed higher FCR compared to PC broilers from 1 to 33 d (1.42 vs. 1.39) (P = 0.048) and from 1 to 42 d (1.51 vs. 1.49) (P < 0.001). V1500 broilers had fewer intestinal lesions at 28 d when compared to the PC treatment (P < 0.05) and showed that higher Viligen inclusion resulted in lower intestinal damage. At 21 d, the V500 group showed higher intestinal morphology characteristics (VH:VD 4.9 vs. 3.5) compared to the PC treatment (P < 0.001). Thus, in this study, the dietary addition of Viligen to broilers challenged by an experimental model of subclinical NE resulted in lower intestinal damage and similar performance to that obtained by the addition of Enramycin.
Most autoinflammatory diseases are caused by mutations in innate immunity genes. Previously, four variants in the RHO GTPase CDC42 were discovered in patients affected by syndromes generally characterized by neonatal-onset of cytopenia and auto-inflammation, including hemophagocytic lymphohistiocytosis and rash in the most severe form (NOCARH syndrome). However, the mechanisms responsible for these phenotypes remain largely elusive. Here, we show that the recurrent p.R186C CDC42 variant, which is trapped in the Golgi apparatus, elicits a block in both anterograde and retrograde transports. Consequently, it favours STING accumulation in the Golgi in a COPI-dependent manner. This is also observed for the other Golgi-trapped p.*192 C*24 CDC42 variant, but not for the p.Y64C and p.C188Y variants that do not accumulate in the Golgi. We demonstrate that the two Golgi-trapped CDC42 variants are the only ones that exhibit overactivation of the STING pathway and the type I interferon response, and elicit endoplasmic reticulum stress. Consistent with these results, patients carrying Golgi-trapped CDC42 mutants present very high levels of circulating IFNα at the onset of their disease. In conclusion, we report further mechanistic insights on the impact of the Golgi-trapped CDC42 variants. This increase in STING activation provides a rationale for combination treatments for these severe cases.
The trial was designed to investigate the safety and outcome of allogeneic filgrastim-mobilized PBPCT compared with allogeneic BMT in patients with standard-risk leukemia. A total of 350 patients between 18 and 55 years of age with acute leukemias in remission or chronic myelogenous leukemia in first chronic phase were randomized to receive either filgrastim-mobilized peripheral blood progenitor cells or bone marrow cells from HLA-identical sibling donors after standard high-dose chemoradiotherapy. The study was approved by the ethics committees of all participating centers, and all patients and donors gave informed consent before any study-related procedure was performed. Donor-recipient pairs were randomized to undergo either BMT or PBPCT. Randomization was carried out centrally at the International Institute for Drug Development (id2), Brussels, Belgium, and used the minimization method to allocate donor and recipient to allogeneic BMT or PBPCT. The randomization strata were as follows: diagnosis (chronic myeloid leukemia \[CML\] vs other diseases), sex mismatch of donor and recipient, and whether the donor was female and nulliparous. Follow-up visits were scheduled for 6, 12, 24, and 36 months after the date of transplantation.

Neutrophil and platelet recovery occurred significantly faster after transplantation of peripheral blood progenitor cells than after bone marrow transplantation. Acute graft versus host disease of grades II-IV was significantly more frequent in recipients of peripheral blood progenitor cells than in recipients of marrow cells The cumulative incidence of chronic graft versus host disease was higher with peripheral blood progenitor cells than with bone marrow cells
The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual.
The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
Immunosuppression drugs, like antibiotics and certain foods, can change the microbiome (the natural micro-organisms inside the body) of the individual taking the drug. The study team wants to study what impact these changes to the microbiome have on the individual. The study team is specifically interested in how these changes to the microbiome may change the metabolism (breakdown) and action of medications. It is already known that individual genetics impact the metabolism, absorption, and toxicities of some medications. It is suspected that the microbiome will have similar impacts on medications. With a better understanding of how individual microbiome impacts immunosuppressant medications used to help transplant recipients from rejecting their new organs, providers can more accurately prescribe and dose these medications to better treat and care for transplant patients and their organs.

It is expected that participants will be in this research study for up to 12 years. There will be periods of time that requires active participation (visits) and periods of time that will be more passive participation (allowing study staff to follow-up with medical records for outcomes).
Belonging to the field of biotechnologies, the invention provides a group of chymotrypsin nucleic acid aptamers, a preparation method and application thereof. The invention also provides a chymotrypsin reactor and its preparation method. Directed at the defect of absence of a chymotrypsin nucleic acid aptamer, the invention provides a group of chymotrypsin nucleic acid aptamers, the nucleotide sequences of which are selected from SEQ ID No.1-SEQ ID No.27 in a sequence table. The chymotrypsin nucleic acid aptamers are prepared through screening, amplifying and sequencing original random oligonucleotide libraries by means of the SELEX (systematic evolution of ligands by exponential enrichment) technology combined with the use of surface modified magnetic beads. The chymotrypsin nucleic acid aptamers of the invention can be used for detection, separation, purification and immobilization of chymotrypsin, and for preparing biosensors, analyzing and detecting a target substance and preparing reagents for clinical diagnosis and medicaments for treating diseases, as well as for preparing chymotrypsin reactors. With small molecular weight, the nucleic acid aptamers can be synthesized chemically at a low cost. The nucleic acid aptamers of the invention have the advantages of strong affinity and specificity, convenience for marking, good repeatability and stability, and easy preservation.
CKD is based on estimated GFR calculated by the MDRD method of \< 60 mL/min/1.73m\^2. Anemia is defined as Hemogloblin \<12 g/dL in women, \< 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.